On January 6, the freeze-dried herpes zoster virus mRNA vaccine independently developed by Beijing Kexing Zhongwei Biotechnology Co., Ltd., a subsidiary of Kexing Group, was officially enrolled in phase I/II clinical research. The vaccine is used to prevent shingles in people aged 40 and above. According to Kexing, this study uses a randomized, double-blind, controlled trial design. Volunteers will be randomly assigned to the test vaccine group, positive control group, or placebo group to evaluate the safety and immunogenicity of different doses of the freeze-dried herpes zoster virus mRNA vaccine in people aged 40 and above.

On January 6, the freeze-dried herpes zoster virus mRNA vaccine independently developed by Beijing Kexing Zhongwei Biotechnology Co., Ltd., a subsidiary of Kexing Group, was officially enrolled in phase I/II clinical research. The vaccine is used to prevent shingles in people aged 40 and above. According to Kexing, this study uses a randomized, double-blind, controlled trial design. Volunteers will be randomly assigned to the test vaccine group, positive control group, or placebo group to evaluate the safety and immunogenicity of different doses of the freeze-dried herpes zoster virus mRNA vaccine in people aged 40 and above.